You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

70 Results
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: GL-C50-24
Version: 3
Jan 2024
Drug
Other Name(s): Alimta®
Apr 2023
Drug
Feb 2024
Drug
Other Name(s): Pomalyst®
Aug 2023
Drug
Other Name(s): Iclusig®
Aug 2023
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
    procarbazine
ODB - General Benefit
    lomustine
Jan 2023
Regimen
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Sarcoma, 
Kaposi's Sarcoma
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Nov 2024

Pages